PhRMA Celebrates 20th Anniversary of Discoverers Award
Honors Coreg® Researchers at Capitol Hill Press Conference

Washington, D.C. (February 7, 2008) — Pharmaceutical Research and Manufacturers
of America (PhRMA) today honored recipients of PhRMA’s 2008 Discoverers Award and
this year’s Clinical Trial Exceptional Service Award at a Capitol Hill news conference.

PhRMA presented the Discoverers Award – its highest honor – and the Clinical Trial
Exceptional Service Award to biopharmaceutical company scientists and other
researchers who helped discover and advance Coreg, a breakthrough medicine that has
helped improve the lives of more than five million patients worldwide.

Billy Tauzin (left), President and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA), and Research!America President Mary Woolley flank PhRMA's 2008 Discoverers Award honorees, Tian-Li Yue, Ph.D., Eliot Ohlstein, Ph.D., and Robert Ruffolo Jr., Ph.D.

GlaxoSmithKline’s (GSK) cardiovascular medicine Coreg has reduced the mortality of
congestive heart failure and changed the paradigm for treating this life-threatening and
debilitative disease. Coreg is also used by patients to treat high blood pressure and
prevent recurrent heart attacks.

This year marks the 20-year anniversary of the Discoverers Award. The award recognizes
scientists whose research and development of medicines have greatly benefited mankind,
and whose dedication to improving the quality of patients’ lives exemplify the best among
research based company scientists today.

This year, PhRMA presented the Discoverers Award to the three then SmithKline
Beecham scientists who discovered the prescription drug Coreg. The recipients of the
award are Eliot Ohlstein, Ph.D., Senior Vice President and head of the Cardiovascular &
Urogenital Diseases Center of Excellence for Drug Discovery at GSK; Robert Ruffolo, Jr.,
Ph.D., formerly an R&D executive at the GSK heritage company and now President,
Research & Development at Wyeth; and Tian-Li Yue, Ph.D., Manager, Department of
Investigative & Cardiac Biology, Cardiovascular Urogenital Centre of Excellence in Drug
Discovery at GSK. All of these honorees reside in the Philadelphia, Pennsylvania area.

At the press conference, PhRMA also bestowed the annual Clinical Trial Exceptional
Service Award to Michael Bristow, M.D., Ph.D., Co-Director, University of Colorado
Cardiovascular Institute; Mary Ann Lukas, M.D., F.A.C.C., Senior Director, Cardiovascular
Medicine Development Centre at GSK; and Milton Packer, M.D., Director, Center for
Biostatistics and Clinical Science and Professor at the University of Texas Southwestern
Pharmaceutical Research and Manufacturers of America Medical Center. All three researchers helped make extraordinary advances in the clinical trials that were essential to the development of Coreg.

Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Billy Tauzin (left) and Research!America President Mary Woolley (right) congratulate PhRMA's 2008 Clinical Trial Exceptional Service Award honorees Mary Ann Lukas, M.D. (second from left); Milton Packer, M.D.; Michael Bristow, M.D., Ph.D.; and patient Lacey Angioletti

The Clinical Trial Exceptional Service Award also was presented to Lacey Angioletti, a
patient who participated in the clinical trials of the life-saving treatment Coreg. Angioletti
was only 21-years old when she was diagnosed with heart failure. Now at age 34,
Angioletti is an actress and thankfully leading a healthy life, due in large part, to this
prescription medicine.

PhRMA’s President and CEO Billy Tauzin, in his remarks at the press conference said,
“The recipients of these Awards should all be proud that they played such an incredible
role in advancing health care here in America and around the world. Millions of patients
worldwide now live healthier, longer lives because of the critical research that was done
by these dedicated researchers.” Tauzin added, “These extraordinary honorees certainly
deserve this recognition because they are the heroes behind the miracle medicine that
has helped patients like Lacey win their battle against life-threatening heart diseases.”

Alan Metz, M.D., GlaxoSmithKline's Vice President and Medical Director, North America,
added that, "Coreg is a wonderful example of how creative science can change the
fundamental thinking about the way we treat disease, and how innovation can make a
life-saving difference to patients. The scientists we honor today championed this
achievement, and hundreds of others in GSK shared their vision and passion to make this
medicine a reality. This award honors all of them."

Joining Tauzin and Dr. Metz in presenting PhRMA’s Discoverers Award and Clinical Trial
Exceptional Service Award was Mary Woolley, President and CEO of Research!America,
a group of 500 organizations that advocates for stronger funding and policies for research
to improve health in America.

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $43 billion in 2006 in discovering and developing new medicines. Industry-wide research and investment reached a record $55.2 billion in 2006.

PhRMA Internet Address: www.phrma.org

For information on stories of hope and survival, visit: http://sharingmiracles.com/

PhRMA en Español: www.nuestraphrma.org

For information on how innovative medicines save lives, visit: www.innovation.org

For information on the Partnership for Prescription Assistance, visit: www.pparx.org

For information on the danger of imported drugs, visit: www.buysafedrugs.info